Skip to content
lifestyle.independent.mk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cosmos Health Inc.
Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines
June 15, 2026
Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries
June 11, 2026
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation
May 26, 2026
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
May 24, 2026
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders’ Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
May 24, 2026
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB’s Venture Debt Program
May 23, 2026
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
May 23, 2026
Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed
May 22, 2026
Cosmos Health Introduces Fort18 in the United States – A Men’s Sexual Stamina Supplement Expanding the 18 Series into Men’s Wellness
May 16, 2026
Cosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK’s Second-Largest Beauty and Health Retailer
February 18, 2026
←
Previous Page
1
2
3